Inhibition of aberrant PI3K/Akt signaling by perifosine in various cancer types including thyroid cancer (Liu et al., 2009), renal cell carcinoma (Porta and Figlin, 2009), neuroblastoma (Sun and Modak, 2012), neuroendocrine tumors (Zitzmann et al., 2012), mantle cell lymphoma (Reis-Sobreiro et al., 2013), and multiple myeloma (Cirstea et al., 2010) seems to be a promising therapeutic strategy. The gene discussed is AKT1; the disease is thyroid cancer.